Maria-Corina Serban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria-Corina Serban has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Amirhossein Sahebkar
Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
6 shared publications- Maciej Banach
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland
6 shared publications - Sorin Ursoniu
Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy, No. 2, Eftimie Murgu Sq., 300041 Timisoara, Romania
6 shared publications - Florina Andrica
Faculty of Pharmacy, Discipline of Pharmaceutical Chemistry "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania
3 shared publications Dimitri P. Mikhailidis
Department of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London (UCL), London, UK
2 shared publicationsGregory Y.H. Lip
University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
2 shared publications
Latest Publications
- 21 September 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 21 (11) , 1006-1015
Curcumin Therapeutic Modulation of the Wnt Signaling Pathway
Curcumin, isolated from the rhizome of Curcuma longa, is one of the most extensively studied phytochemicals. This natural compound has a variety of pharmacological effects including antioxidant, anti-inflammatory, anti-tumor, cardio-protective, hepato-protective and anti-diabetic. Wnt signaling pathway, one of the potential targets of curcumin through upregulation and/or downregulation, plays a significant role in many diseases, even in embryogenesis and development of various organs and systems. In order to exert an anti-tumor activity in the organism, curcumin seems to inhibit the Wnt pathway. The downstream mediators of Wnt signaling pathway such as c-Myc and cyclin D1 are also modified by curcumin. This review demonstrates how curcumin influences the Wnt signaling pathway and is beneficial for the treatment of neurological disorders (Alzheimer’s and Parkinson’s diseases), cancers (melanoma, lung cancer, breast cancer, colon cancer, endothelial carcinoma, gastric carcinoma and hepatocellular carcinoma) and other diseases, such as diabetes mellitus or bone disorders.
- 21 September 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 21 (11) , 1006-1015
Curcumin Therapeutic Modulation of the Wnt Signaling Pathway
Curcumin, isolated from the rhizome of Curcuma longa, is one of the most extensively studied phytochemicals. This natural compound has a variety of pharmacological effects including antioxidant, anti-inflammatory, anti-tumor, cardio-protective, hepato-protective and anti-diabetic. Wnt signaling pathway, one of the potential targets of curcumin through upregulation and/or downregulation, plays a significant role in many diseases, even in embryogenesis and development of various organs and systems. In order to exert an anti-tumor activity in the organism, curcumin seems to inhibit the Wnt pathway. The downstream mediators of Wnt signaling pathway such as c-Myc and cyclin D1 are also modified by curcumin. This review demonstrates how curcumin influences the Wnt signaling pathway and is beneficial for the treatment of neurological disorders (Alzheimer’s and Parkinson’s diseases), cancers (melanoma, lung cancer, breast cancer, colon cancer, endothelial carcinoma, gastric carcinoma and hepatocellular carcinoma) and other diseases, such as diabetes mellitus or bone disorders.
- Open Access
- 24 August 2017
- Published by Taylor & Francis in Critical Reviews in Food Science and Nutrition
- Vol. 58 (10) , 1706-1714
Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review
Coffee consumption alters plasma lipid and cholesterol concentrations, however, its effects on lipoprotein(a) (Lp(a)) have received little study. The aim of this PRISMA compliant systematic review was to examine the role of coffee on serum Lp(a). This study was prospectively registered (PROSPERO 2015:CRD42015032335). PubMed, Scopus, Web of Science and Cochrane Central were searched from inception until 9th January 2016 to detect trials and epidemiological studies investigating the impact of coffee on serum Lp(a) concentrations in humans. We identified six relevant publications describing nine experimental trials of various designs. There were a total of 640 participants across all studies and experimental groups. In short-term controlled studies, consumption of coffee, or coffee diterpenes was associated with either a reduction in serum Lp(a) of ≤11 mg/dL (6 trials, 275 participants), or no effect (2 trials, 56 participants). Conversely, one cross-sectional study with 309 participants showed serum Lp(a) was elevated in chronic consumers of boiled coffee who had a median Lp(a) of 13.0 mg/dL (range 0–130) compared with consumers of filtered coffee who had median Lp(a) 7.9 mg/dL (range 0–144). The effect of coffee on Lp(a) is complex and may follow a biphasic time-course. The type of coffee and the method of preparation appear to be important to determining the effect on Lp(a).
- 24 August 2017
- Published by Taylor & Francis in Critical Reviews in Food Science and Nutrition
- Vol. 58 (10) , 1706-1714
Open AccessDoes coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review
Coffee consumption alters plasma lipid and cholesterol concentrations, however, its effects on lipoprotein(a) (Lp(a)) have received little study. The aim of this PRISMA compliant systematic review was to examine the role of coffee on serum Lp(a). This study was prospectively registered (PROSPERO 2015:CRD42015032335). PubMed, Scopus, Web of Science and Cochrane Central were searched from inception until 9th January 2016 to detect trials and epidemiological studies investigating the impact of coffee on serum Lp(a) concentrations in humans. We identified six relevant publications describing nine experimental trials of various designs. There were a total of 640 participants across all studies and experimental groups. In short-term controlled studies, consumption of coffee, or coffee diterpenes was associated with either a reduction in serum Lp(a) of ≤11 mg/dL (6 trials, 275 participants), or no effect (2 trials, 56 participants). Conversely, one cross-sectional study with 309 participants showed serum Lp(a) was elevated in chronic consumers of boiled coffee who had a median Lp(a) of 13.0 mg/dL (range 0–130) compared with consumers of filtered coffee who had median Lp(a) 7.9 mg/dL (range 0–144). The effect of coffee on Lp(a) is complex and may follow a biphasic time-course. The type of coffee and the method of preparation appear to be important to determining the effect on Lp(a).
- 1 October 2016
- Published by Elsevier in Phytomedicine
- Vol. 23 (11) , 1095-1102
Effects of supplementation with pomegranate juice on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials
- 1 October 2016
- Published by Elsevier in Phytomedicine
- Vol. 23 (11) , 1095-1102
Effects of supplementation with pomegranate juice on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials
- 1 August 2016
- Published by Elsevier in Clinical Nutrition
- Vol. 35 (4) , 842-851
A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations
- 1 August 2016
- Published by Elsevier in Clinical Nutrition
- Vol. 35 (4) , 842-851
A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations
- 1 June 2016
- Published by Elsevier in Clinical Nutrition
- Vol. 35 (3) , 615-625
Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial
- 1 June 2016
- Published by Elsevier in Clinical Nutrition
- Vol. 35 (3) , 615-625
Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial
- Open Access
- 1 October 2015
- Published by Elsevier in Journal of Functional Foods
- Vol. 18, 898-909
Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials
- 1 October 2015
- Published by Elsevier in Journal of Functional Foods
- Vol. 18, 898-909
Open AccessEffect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials
- 1 September 2015
- Published by Elsevier in Pharmacological Research
- Vol. 99, 329-336
Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials
- 1 September 2015
- Published by Elsevier in Pharmacological Research
- Vol. 99, 329-336
Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials
- Open Access
- 13 May 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 9902
A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations
The impact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been conclusively studied. Therefore the aim of the meta-analysis was to assess the effect of statins on circulating ADMA levels. We searched selected databases (up to August 2014) to identify randomized controlled trials (RCTs) that investigate the effect of statins on plasma ADMA concentrations. A weighted meta-regression (WMD) using unrestricted maximum likelihood model was performed to assess the impact of statin dose, duration of statin therapy and baseline ADMA concentrations as potential variables on the WMD between statin and placebo group. In total, 1134 participants in 9 selected RCTs were randomized; 568 were allocated to statin treatment and 566 were controls. There was a significant reduction in plasma ADMA concentrations following statin therapy compared with placebo (WMD: − 0.104 μM, 95% confidence interval: − 0.131 to − 0.077, Z = − 7.577, p < 0.0001). Subgroups analysis has shown a significant impact of hydrophilic statins (WMD: − 0.207 μM, 95%CI: − 0.427 to + 0.013, Z = − 7.250, p < .0001) and a non-significant effect of hydrophobic statins (WMD: − 0.101 μM, 95%CI: − 0.128 to − 0.074, Z = − 1.845, p = 0.065). In conclusion, this meta-analysis of available RCTs showed a significant reduction in plasma ADMA concentrations following therapy with hydrophilic statins.
- 13 May 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 9902
Open AccessA systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations
The impact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been conclusively studied. Therefore the aim of the meta-analysis was to assess the effect of statins on circulating ADMA levels. We searched selected databases (up to August 2014) to identify randomized controlled trials (RCTs) that investigate the effect of statins on plasma ADMA concentrations. A weighted meta-regression (WMD) using unrestricted maximum likelihood model was performed to assess the impact of statin dose, duration of statin therapy and baseline ADMA concentrations as potential variables on the WMD between statin and placebo group. In total, 1134 participants in 9 selected RCTs were randomized; 568 were allocated to statin treatment and 566 were controls. There was a significant reduction in plasma ADMA concentrations following statin therapy compared with placebo (WMD: − 0.104 μM, 95% confidence interval: − 0.131 to − 0.077, Z = − 7.577, p < 0.0001). Subgroups analysis has shown a significant impact of hydrophilic statins (WMD: − 0.207 μM, 95%CI: − 0.427 to + 0.013, Z = − 7.250, p < .0001) and a non-significant effect of hydrophobic statins (WMD: − 0.101 μM, 95%CI: − 0.128 to − 0.074, Z = − 1.845, p = 0.065). In conclusion, this meta-analysis of available RCTs showed a significant reduction in plasma ADMA concentrations following therapy with hydrophilic statins.
- 1 March 2011
- Published by Elsevier in Journal of Electrocardiology
- Vol. 44 (2) , 105-108
Factors associated with a prolonged QT interval in liver cirrhosis patients
- 1 March 2011
- Published by Elsevier in Journal of Electrocardiology
- Vol. 44 (2) , 105-108
Factors associated with a prolonged QT interval in liver cirrhosis patients